
We see precision medicine as the future of cancer care.
Let’s make it happen, together. Our cutting-edge genomic profiling technology covers all cancer and sample types to accelerate precision cancer care. We work closely with you to solve your specific needs, with a relentless focus on quality and efficiency.
EXPERIENCE MATTERS.WE HAVE IT.
Services for Oncology Clinical Trials
-
- NGS services
- CDx + LDT strategy
- Project management
- Sample logistics and storage
- Data analysis and storage
- Customized QC/QA solutions
NGS Services for Precision Oncology
-
- Pan-cancer genetic test for solid tumors
- ctDNA liquid biopsy
- Over 30 clinical NGS testing products for different cancers
- Over 10 products under development
NGS-based CDx Kit for Diagnosis
-
- Essencare ™ EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutant testing kit (reversible terminator technology)
NGS Services for Research
-
- DNA sequencing
- WGS, WES
- Targeted panel sequencing
- DNA methylation sequencing
- Customer-made library sequencing
- RNA sequencing
- Whole transcriptome sequencing
- Small RNA sequencing, including miRNA, siRNA and piRNA
- Circular RNA sequencing
- DNA sequencing
1,500,000+
SAMPLES
sequenced for cancer patients
800+
HOSPITALS
in which our products are used
60+
PRODUCTS
for solid tumors & blood cancers
3,000+
CLINICAL PROJECTS
in translational research
950+
PUBLICATIONS
in the past 5 years
Certified to the highest international clinical lab standards




Genomic Testing
The most diverse range of cancer genomic testing available
Using comprehensive genomic insights, we help match cancer patients to optimal treatments, including targeted therapy and immunotherapy. Our pan-cancer panel analyzes 400+ genes, while our cancer-specific panels target individual cancer types. We partner with you to give you the insights you need to take action – from treatment decisions to development of novel therapies.
Research Services
A strong partner to drive research forward
Our company is built on a strong foundation of research, with deep scientific expertise and active R&D. We have 2000+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We offer start-to-finish research services, including project design & management, next-generation sequencing, QC/QA and data analysis, tailored to your needs.


OUR TECHNOLOGY
Reliable and fast is possible
We are continuously evolving our sequencing technology as advancements are made in the field. This ensures an optimized workflow – from sample preparation, mutation calling and data mining to machine-learning and exclusive genomic databases – with a very high sequencing capacity. To date, we have sequenced 900,000+ samples (including 360,000+ liquid biopsy samples), with high sensitivity and specificity and a turnaround time of just five business days.
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
Our News
August 11, 2026
Geneseeq Expands PanTRKare™ with a Third NMPA-Approved CDx Application for VELMARTO® (Eratrectinib)
TORONTO, Canada - August 11, 2026 - Geneseeq Technology Inc., a…
July 14, 2026
Geneseeq Canada Named First Genomic Testing Partner in UHN’s SHERLOCK Study
Collaboration supports genomic profiling and molecular monitoring…
November 10, 2025
Geneseeq Receives NMPA Approval for PanTRKare™ – China’s First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions
Toronto, Canada — [November 10, 2025] — Geneseeq Technology Inc., a…
September 29, 2025
Geneseeq Validates Cell-free DNA Blood Test for Early Detection of Pancreatic Cancer in a Prospective Study
Toronto, Canada – Geneseeq and its clinical collaborators have…
September 2, 2025
GeneseeqPrime® Gains FDA 510(k) Clearance
With FDA., CE-IVD, and NMPA approvals, the comprehensive tumor…
May 28, 2025
Geneseeq’s Breakthrough Cancer Detection Blood Test Published in Nature Medicine
Large-Scale Study Confirms CanScan® Test Accurately Detects…
May 21, 2025
Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025
[Toronto, May 21, 2025] - Geneseeq Technology Inc., shared today that…
May 7, 2025
Geneseeq Unveils Groundbreaking Blood Test for Early Detection of Pancreatic Cancer
May 7, 2025– Geneseeq Technology Inc., in collaboration with leading…
December 3, 2024
GENESEEQ’S NGS LIQUID BIOPSY KIT MARKS THE FIRST TO ENTER NMPA’S SPECIAL REVIEW AND APPROVAL OF INNOVATIVE MEDICAL DEVICE
Recently, the National Medical Products Administration (NMPA)…
July 3, 2024
Geneseeq partners with Jiangsu Vcare PharmaTech to develop a CDx for NTRK inhibitor in China.
July 3, 2024, Toronto - Geneseeq Technology Inc. announced this week…
Stay in the loop! Subscribe our newsletter
Error: Contact form not found.
